Healthcare Valuation Multiples by Sector and Specialty (2026)
Private healthcare businesses sold at medians from 3.4x SDE under $500,000 of earnings to 12.9x EBITDA above $10 million in Axia Growth's closed-sale data (as of October 28, 2026). Listed healthcare groups trade at 8.86x to 21.27x EBITDA (Damodaran, January 2026). Size moves a private multiple more than specialty does.
The 2026 numbers at a glance
| Benchmark | Multiple | Population, source and as-of date |
|---|---|---|
| Listed healthcare IT | 21.27x EV/EBITDA | 115 US listed firms, Damodaran, January 2026 |
| Listed hospitals and facilities | 8.86x | 31 US listed firms, Damodaran, January 2026 |
| Healthcare M&A median | 11.6x | PitchBook data reported by Sikich, 2026 year to date in Sikich's Q3 2026 update. 14.5x in 2024 |
| PE-backed healthcare services median | 13.6x | PitchBook data reported by Sikich, 2025 deals, about $33M implied target EBITDA |
| US healthcare services control deals | 9.6x median (10.1x excluding distressed) | Buckhead FMV, 68 deals with positive EBITDA out of 187, announced January 2023 to October 31, 2026 |
| Closed healthcare-sector sales, $5M to $10M EBITDA | 8.8x median | Axia Growth, 14 sales, as of October 28, 2026 |
| Closed healthcare-sector sales, $10M+ EBITDA | 12.9x median, middle half 9.4x to 18.5x | Axia Growth, 17 sales, as of October 28, 2026 |
| Dermatology, solo practice to large platform | 3x to 15x typical | FOCUS Investment Banking 2026 tiers, no deal count published |
Compiled November 2026. Each row carries its own population and date. Listed-company multiples price minority shares. Private figures price control. Read the two as different markets.
Which Benchmark Fits Your Business
Start here. Pick the row that matches your business, use the primary benchmark, then test it against the cross-check.
| Your business | Primary benchmark | Cross-check | Do not anchor on |
|---|---|---|---|
| Practice under $1M of owner earnings | Axia 3.4x SDE median (as of October 28, 2026) | Sikich 5x to 7x EBITDA below $1M (Q3 2026), after converting SDE to EBITDA | Public sector multiples |
| Practice group, $1M to $5M EBITDA | Sikich 7x to 9x ($1M to $3M) and 9x to 11x ($3M to $5M), Q3 2026 | Axia 5.1x median at $2M to $3M EBITDA | PitchBook's 13.6x platform median |
| Group or platform, $5M to $10M EBITDA | Axia 8.8x median, 10.7x top quarter | Sikich 11x to 13x above $5M EBITDA | Damodaran group multiples |
| Platform above $10M EBITDA | Axia 12.9x median, 9.4x to 18.5x middle half | PitchBook 13.6x PE-backed services median, 2025 | Small-deal medians |
| Dermatology at any size | FOCUS 2026 tier for your revenue | Axia band for your EBITDA | Another specialty's tier |
| Dental | Sikich DSO ranges: practices 5x to 9x, add-ons 5x to 8x, platforms 9x to 11x | Axia band for your earnings | Physician practice bands |
| ASC | Sikich: single-specialty 5x to 8x, multispecialty 6x to 10x, regional operators 11x to 17x | Buckhead 12.4x (control deals, 2023 to October 2026) | Buckhead's median for a single center |
| Hospital | Buckhead 9.5x on positive-EBITDA control deals | Damodaran 8.86x, Sikich public comps 6.1x to 8.5x (June 30, 2026) | EBITDA multiples on a loss-making hospital |
| Healthcare IT | Damodaran 21.27x as a ceiling, January 2026 | Strategic premium per FOCUS 2026 dashboard | Services multiples |
Public Healthcare EV/EBITDA by Sector, January 2026 (Damodaran, NYU Stern)
Aswath Damodaran's January 2026 EV/EBITDA dataset is the cleanest free public baseline. Each industry row carries several versions of the multiple. This page cites one EV/EBITDA figure per group throughout. If a buyer quotes a different Damodaran figure for the same group, ask which column and which date.
| Sector (Damodaran label) | US listed firms | EV/EBITDA, January 2026 | What it tells a private owner |
|---|---|---|---|
| Healthcare Information and Technology | 115 | 21.27x | Buyers pay for recurring software and data revenue |
| Healthcare Products | 204 | 19.78x | Patented products carry a premium |
| Drugs (Biotechnology) | 496 | 15.78x | Pipeline value. Rarely a comp for a services business |
| Drugs (Pharmaceutical) | 228 | 15.25x | Like biotech, with more mature cash flow |
| Healthcare Support Services | 104 | 11.17x | A pass-through revenue profile (0.46x EV/Sales, 12.08% gross margin, 3.21% EBITDA margin). Not a practice comp |
| Hospitals/Healthcare Facilities | 31 | 8.86x | Capital-heavy and reimbursement-dependent. Lowest of the six |
Public company trading multiples. Private practices usually trade below these.
Chart data
| Healthcare IT | 21.27 |
|---|---|
| Healthcare products | 19.78 |
| Total market ex-financials | 16.95 |
| Biotechnology | 15.78 |
| Pharmaceutical | 15.25 |
| Healthcare support services | 11.17 |
| Hospitals and facilities | 8.86 |
Source: Aswath Damodaran, NYU Stern, EV/EBITDA by industry, January 2026
Reference points from the same January 2026 dataset. Software (System & Application) trades at 24.48x, 3.21 turns above listed healthcare IT (our arithmetic). Education, another labor-heavy regulated service, trades at 9.26x, 0.40 turns above hospitals. Machinery (16.22x) and Engineering/Construction (17.18x) both sit above healthcare support services.
These multiples price minority stakes in listed companies with audited financials, professional management and daily liquidity. A practice buyer takes the whole business, holds it for years and inherits everything that depends on the owner. Use the table as a sector ceiling, not a private benchmark.
No Damodaran group isolates physician practice management. Healthcare Support Services carries the closest-sounding name, but its margins describe a different business. A 12.08% gross margin and 0.46x EV/Sales are the profile of large firms that pass most revenue through to suppliers or claims, such as distribution and managed care. A physician group keeps far more of each revenue dollar. Neither the group's 11.17x nor its 3.21% margin belongs in a practice valuation.
Decision rule. If a letter of intent cites a public comp, ask which Damodaran group and date it uses, which companies sit in that group, and how many turns the buyer subtracted for your size and illiquidity, on what evidence.
Cross-Checking a Multiple With EV/Sales and Margins (Damodaran, January 2026)
A multiple hides the margin underneath it. Damodaran's EV/Sales page and margins page, both as of January 2026, give that data for the same six groups.
| Damodaran group | EV/Sales | Pre-tax operating margin | EBITDA margin | Gross margin |
|---|---|---|---|---|
| Drugs (Biotechnology) | 7.92x | 8.76% | 16.17% | 60.78% |
| Drugs (Pharmaceutical) | 6.24x | 29.54% | 31.24% | 71.73% |
| Healthcare Products | 4.76x | 15.47% | 17.40% | 54.00% |
| Healthcare Information and Technology | 5.31x | 14.75% | 17.12% | 48.32% |
| Hospitals/Healthcare Facilities | 1.69x | 12.86% | 14.05% | 39.10% |
| Healthcare Support Services | 0.46x | 2.99% | 3.21% | 12.08% |
| Total market (5,994 firms) | 3.97x | 12.75% | 14.39% | 37.76% |
Operating income vs EBITDA. Operating income is revenue minus operating expenses, and depreciation and amortization are counted among those expenses. EBITDA adds depreciation and amortization back to operating income. That is why every EBITDA margin in the table sits above its operating margin. The gap is widest where assets or acquired intangibles are heavy.
The identity. For one company, EV/Sales divided by EBITDA margin equals EV/EBITDA, because revenue cancels. It holds only when enterprise value, revenue and EBITDA share one definition and one twelve-month period.
Why it fails on group data. The table below is our arithmetic, applying the identity to Damodaran's group figures. The last column divides our implied EV/EBITDA by Damodaran's reported EV/EBITDA.
| Damodaran group | Implied EV/EBITDA: EV/Sales ÷ EBITDA margin (our arithmetic) | Reported EV/EBITDA | Ratio of implied to reported |
|---|---|---|---|
| Healthcare Products | 4.76 ÷ 0.1740 = 27.36x | 19.78x | 1.38 |
| Healthcare Support Services | 0.46 ÷ 0.0321 = 14.33x | 11.17x | 1.28 |
| Healthcare Information and Technology | 5.31 ÷ 0.1712 = 31.02x | 21.27x | 1.46 |
| Hospitals/Healthcare Facilities | 1.69 ÷ 0.1405 = 12.03x | 8.86x | 1.36 |
| Drugs (Biotechnology) | 7.92 ÷ 0.1617 = 48.98x | 15.78x | 3.10 |
| Drugs (Pharmaceutical) | 6.24 ÷ 0.3124 = 19.97x | 15.25x | 1.31 |
Every implied figure overshoots, by 28% to 46% outside biotech and by about three times for biotech. Each group figure aggregates firms with very different margins, and the EV/Sales and margin pages weight them differently. Biotech's negative 5.00% net margin points to many loss-making firms, which is why its gap is widest. Run the identity on one company's own numbers. Never pair a revenue multiple from one source with a margin from another.
Medians can't be divided either. Buckhead FMV reports hospitals at a median 0.41x revenue and 9.5x EBITDA. Dividing one by the other suggests a 4.3% margin, and that figure describes no actual hospital. The revenue median covers every hospital deal with reported revenue. The EBITDA median covers only deals with positive, disclosed EBITDA, which screens out most distressed sellers. Two medians from different deal sets don't combine into a third statistic.
Using it on a real offer. Example, hypothetical figures, our arithmetic. Basis: adjusted EBITDA for the same trailing twelve months as revenue. A $40 million offer on $25 million of trailing revenue is 1.6x EV/Sales. At a 20% adjusted EBITDA margin, that implies 8.0x. If the letter says 9x, the buyer is pricing $40 million ÷ 9 = about $4.44 million of EBITDA, not your $25 million × 20% = $5.0 million. It has rejected about $0.56 million of add-backs. Ask which ones.
Why public multiples overstate what a private practice gets:
- Size. One lost physician or one closed site barely moves a listed company's EBITDA.
- Liquidity. Public shares sell the same day. A practice buyer holds for years and charges for it.
- Payer mix. A practice's EBITDA often rests on a few commercial contracts plus government rates it can't negotiate.
- Margin sensitivity. The thinner the margin, the harder a revenue loss hits EBITDA. Example, our arithmetic, holding every cost fixed: a 1% revenue loss cuts EBITDA by 10% at a 10% EBITDA margin and by 5% at a 20% margin.
Public vs Private Pricing in 2026: PitchBook's Slide From 14.5x to 11.6x
PitchBook's median healthcare M&A multiple, as reported by Sikich, fell from 14.5x EV/EBITDA in 2024 to 13x in 2025 and 11.6x for 2026 year to date in Sikich's Q3 2026 update. Sikich reports that PitchBook's trailing-twelve-month healthcare median of 12.7x still leads every sector. Median EV/revenue held at 2.4x.
Platform pricing held while the market median fell. In the same PitchBook data, the median PE-backed healthcare services company sold at 13.6x EBITDA in 2025, against 13.5x in 2024. Implied target EBITDA rose about 27% to roughly $33 million and entry leverage edged up to 5.2x. Buyers are paying the same multiple for bigger targets.
Hospitals, public and private control (different datasets and periods, labeled):
| Measure | Population and period | EV/EBITDA |
|---|---|---|
| Damodaran Hospitals/Healthcare Facilities | 31 US listed firms, minority shares, January 2026 | 8.86x |
| Buckhead FMV hospitals | Control deals with positive disclosed EBITDA, January 2023 to October 2026 | 9.5x |
| Sikich public hospital comps | HCA 8.5x, Community Health 7.5x, Ardent 6.1x, as of June 30, 2026. Long-run public average about 10x | 6.1x to 8.5x |
Reading the hospital numbers. Damodaran's 8.86x prices minority shares that trade daily. Buckhead's 9.5x prices control of whole hospitals over almost four years. Control adds value because the buyer sets strategy and owns the cash flow. Illiquidity and smaller size subtract value. The two figures sit within one turn, but no public dataset separates those effects. An adviser's precise "control premium" is an assumption until they show the deals behind it. Buckhead's 9.5x also covers only hospitals with positive EBITDA. Distressed hospital sales appear in its 0.15x revenue median instead.
Timing. The PitchBook median fell almost three turns between 2024 and 2026 year to date. Before going to market, list anything that would force a sale on a fixed date: a partner retirement, a lease expiry, a loan maturity. A seller with no deadline can turn down low bids and wait.
Four Private Datasets Compared: Buckhead FMV, Axia Growth, PitchBook and FOCUS
Each source counts a different kind of deal. Those differences explain most of the disagreement between them.
| Dataset | Deals behind the numbers | Transaction type | Period | Earnings basis | Main bias |
|---|---|---|---|---|---|
| Buckhead FMV | 187 control deals screened from 215. EBITDA multiples on 68 | Control only. Minority and physician-syndication stakes excluded. Distressed sales included and flagged | Announced January 2023 to October 31, 2026 | EBITDA as reported by the parties or computed from cost reports as net income plus interest, taxes, depreciation and amortization. Shown only where positive | Large and public deals disclose EBITDA more often, so EBITDA medians lean large. Some prices include real estate |
| Axia Growth | 290 healthcare-sector sales across six size bands (our sum), drawn from a 4,554-sale database | Closed small and lower-middle-market sales over $500K. The size table covers the healthcare sector as a whole, published on Axia's physician practice management and MSO page | As of October 28, 2026 | SDE below $2M, EBITDA above. Axia does not state whether EBITDA is adjusted | Top bands rest on 13 to 17 sales each, with wide middle halves |
| PitchBook, reported by Sikich | No deal count in the summary | Market-wide M&A with disclosed multiples, plus a PE-backed services median | 2024 to 2026 year to date, per Sikich's Q3 2026 update | EBITDA | Weighted to sponsor and larger deals |
| FOCUS Investment Banking | No deal count published | Typical ranges by specialty and revenue tier | 2026 edition | EBITDA, tiers set by revenue | One firm's view of typical pricing, not a transaction median |
Buckhead is the most transparent on method. Every price is disclosed or court-approved, with financials from SEC filings, state certificate-of-need and transaction-notice filings, bankruptcy court approvals and Medicare cost reports. Axia is the only source with counted deals at small-practice size. PitchBook gives the market trend. FOCUS gives the clearest specialty ladder.
By year.
| Year | Buckhead control-deal EV/EBITDA median | PitchBook healthcare M&A median (reported by Sikich) |
|---|---|---|
| 2023 | 11.4x | Not reported |
| 2024 | 9.7x | 14.5x |
| 2025 | 6.5x | 13x |
| 2026 to date | 9.1x (announced through October 31) | 11.6x (Sikich Q3 2026 update) |
| Full period | 9.6x on 68 deals (10.1x excluding distressed) | 12.7x trailing twelve months |
PitchBook runs 2.5 to 6.5 turns above Buckhead in each year both report (our arithmetic). The two are not one series. PitchBook's sample leans toward sponsor deals at platform scale, and Buckhead's toward deals with public filings, including hospitals and small practices. Buckhead attributes its 2025 dip to a smaller, more mid-market deal mix rather than a broad repricing. On revenue, Buckhead's median across all 187 deals is 0.88x (0.98x excluding distressed), against PitchBook's 2.4x.
By deal size (Buckhead FMV, enterprise value, January 2023 to October 2026). Deals above $200 million traded at a median 11.2x EBITDA and 1.34x revenue. Deals below $10 million traded at 2.8x EBITDA and 0.27x revenue. Buckhead finds small practice acquisitions price near asset value. Hospital purchases of individual primary care practices, largely in West Virginia, cluster at 0.05x to 0.15x revenue. At that price the buyer pays for equipment and records, not goodwill.
By earnings size (Axia Growth closed healthcare-sector sales, as of October 28, 2026). Axia prices small deals on seller's discretionary earnings, which includes owner pay, so an SDE multiple runs below an EBITDA multiple by construction. Axia publishes no $3M to $5M band.
| Earnings band | Sales | Median multiple | Middle half (25th to 75th percentile) |
|---|---|---|---|
| Under $500K SDE | 182 | 3.4x SDE | 2.7x to 4.2x |
| $500K to $1M SDE | 42 | 3.4x SDE | 2.5x to 4.4x |
| $1M to $2M SDE | 22 | 3.3x SDE | 2.7x to 7.5x |
| $2M to $3M EBITDA | 13 | 5.1x | 3.1x to 10.9x |
| $5M to $10M EBITDA | 14 | 8.8x | 3.4x to 10.7x |
| $10M+ EBITDA | 17 | 12.9x | 9.4x to 18.5x |
Bands under $2M use seller discretionary earnings (SDE); larger bands use EBITDA.
Chart data
| Under $500K SDE (n=182) | 3.4 |
|---|---|
| $500K to $1M SDE (n=42) | 3.4 |
| $1M to $2M SDE (n=22) | 3.3 |
| $2M to $3M EBITDA (n=13) | 5.1 |
| $5M to $10M EBITDA (n=14) | 8.8 |
| $10M+ EBITDA (n=17) | 12.9 |
Source: Axia Growth, Physician Practice Management sales dataset
Sikich physician practice bands (Q3 2026 update, all on EBITDA). 5x to 7x below $1 million of EBITDA, 7x to 9x at $1 million to $3 million, 9x to 11x at $3 million to $5 million, 11x to 13x above $5 million. Sikich adds that, by specialty, platforms command a four- to eight-turn premium over add-on practices.
Reconciling Axia's 8.8x with Sikich's 11x to 13x above $5 million of EBITDA.
- Transaction type. Axia's 14 sales are closed deals with no screen for buyer type. Sikich's bands describe indicative practice pricing, and the top band matches platform-grade pricing.
- Where the ranges meet. Axia's 75th percentile in the band is 10.7x, just under Sikich's 11x floor. Axia's $10M+ median of 12.9x lands inside Sikich's 11x to 13x.
- Size within the band. PitchBook's 13.6x PE-backed median sits on about $33 million of EBITDA, three to six times the $5 million to $10 million band.
Rule for a seller at $5 million to $10 million of EBITDA. 8.8x is the median closed outcome in Axia's data and 10.7x marks the top quarter. Reaching 11x to 13x takes a competitive sponsor process and a business diligence accepts as a platform.
By segment (Buckhead FMV, January 2023 to October 2026). Each segment EBITDA median rests on a fraction of Buckhead's 68 positive-EBITDA deals. Read them as direction and lean on the cross-check where one exists. Segment names below follow Buckhead's labels.
| Segment (Buckhead label) | Buckhead EV/Revenue | Buckhead EV/EBITDA | Cross-check, with source and date |
|---|---|---|---|
| Ambulatory surgery centers | 1.24x | 12.4x | Sikich 2026: single-specialty 5x to 8x, multispecialty 6x to 10x, regional operators 11x to 17x, trending up. 2025 median ASC multiple 7.9x, the highest in at least eight years |
| Outsourced services | 2.8x | 11.6x | No clean public comp. Damodaran Support Services has a pass-through margin profile |
| Hospitals | 0.41x | 9.5x | Damodaran 8.86x, January 2026. Sikich rates hospital pricing flat in 2026 |
| Primary care practices | 0.11x | Not reported | Axia 3.4x SDE for healthcare-sector sales under $1M SDE |
| Distressed sales (22 with reported revenue) | 0.15x | Not reported | Mostly hospitals sold out of the Steward, Prospect and other bankruptcies |
n = deals with positive disclosed EBITDA. Small samples; read as indicative.
Chart data
| HealthTech (n=3) | 31.4 |
|---|---|
| Specialty outpatient facilities (n=4) | 12.4 |
| Outsourced services (n=8) | 11.6 |
| Managed care (n=4) | 9.6 |
| Hospitals (n=26) | 9.5 |
| Home-based services (n=10) | 7.3 |
| Behavioral health (n=2) | 4.4 |
| Professional services (n=9) | 2.8 |
Sub-sectors outside Buckhead's list (Sikich, indicative 2026 pricing):
| Sub-sector | Indicative pricing | Direction vs 2025 |
|---|---|---|
| Dental (DSOs) | Platforms 9x to 11x, add-ons 5x to 8x, practices 5x to 9x | Flat. Practice pricing steady for two years |
| Home health and hospice | Enhabit take-private at 10.2x. Small agencies mid-single digits | Down. Fewer closings, and buyers discount billing and compliance risk |
| Urgent care | 3x to 7x under $10M revenue, 6x to 11x at $10M to $50M, 10x to 15x and up at scale | Size-driven |
| Senior living and skilled nursing | Priced on cap rates. SNF portfolios near 8.6% yield | Up. Senior living cap rates compressed 25 to 50 bp in 2026 |
Where the datasets agree. Hospital EBITDA multiples cluster between about 9x and 10x: Buckhead's 9.5x, Damodaran's 8.86x and Sikich's roughly 10x long-run public average sit within about one turn. Every dataset steps up with size.
Where they disagree. On ASCs, Buckhead's 12.4x sits inside Sikich's regional-operator range, well above Sikich's single-specialty 5x to 8x. A single-specialty center should plan on Sikich's range, not Buckhead's median. On revenue multiples, Buckhead's 0.88x includes hospitals, distressed sales and primary care practices priced near asset value, against PitchBook's 2.4x. On small deals, Buckhead's 2.8x describes mostly asset-value purchases and Axia's small bands run on SDE. Neither describes a profitable group sold to a platform.
What this means for a seller:
- Place your business by size in every dataset before you look at specialty.
- Under $2 million of earnings, expect mid-single digits. An 11x to 13x quote at that size is platform pricing the business hasn't earned.
- Confirm the basis of every quote: SDE or EBITDA, reported or adjusted.
- Avoid selling under distress. Buckhead's distressed sales cleared at a median 0.15x revenue.
- Read the ranges, not just the medians. Axia's $10M+ band runs 9.4x to 18.5x.
See the multiples by segment and deal size charts for the full visual set.
Dermatology's 3x-to-15x Size Ladder and Its 24 Deals in 2025
FOCUS's Dermatology Practice Valuation: 2026 Benchmarks sets out four tiers. They are the clearest published picture of size changing the multiple within one specialty.
| Tier | Revenue or EBITDA band | Typical 2026 EBITDA multiple | What buyers see (FOCUS) |
|---|---|---|---|
| Solo practice | Under $2M revenue | 3x to 5x | Owner-dependent, limited reach, physician-to-physician deals |
| Small group | $2M to $15M revenue | 4x to 7x | Broader provider base, medical and cosmetic mix, growing buyer pool |
| Regional or mid-sized platform | $15M to $50M revenue | 8x to 10x | Centralized management, in-house pathology or Mohs, diversified payor base |
| Large integrated platform | $50M+ revenue or $10M+ EBITDA | 12x to 15x | Institutional infrastructure, multi-state presence, scalable growth |
The solo and small group ranges overlap at 4x to 5x, so at that size the tier alone won't settle price. The step from small group to regional platform fits FOCUS's 2026 dashboard finding that companies above $10 million of revenue often see a 1.5x to 2x jump in multiples. A small group at 4x moved up by that factor lands at 6x to 8x (our arithmetic), meeting the bottom of the regional tier.
This ladder is what makes roll-ups pay. Example, hypothetical, our arithmetic: a platform buys a solo practice earning $1 million of EBITDA at 4x for $4 million. If the platform later sells at 12x, that $1 million accounts for $12 million of the sale price. The $8 million difference is multiple arbitrage, and it is gross. Integration costs money, acquisition debt needs servicing and some physicians leave after closing.
Sikich's 2026 bands put practices below $1 million of EBITDA at 5x to 7x. Above that line, the bands rise and the four- to eight-turn platform premium Sikich reports becomes reachable.
The buyer pool is large. Axia Growth, citing PAI-Avalere, reports that 82.0% of U.S. physicians were employed by hospitals or corporate entities as of January 1, 2026: 59.7% by hospitals and 22.3% by corporate entities such as PE firms or insurers. Corporate owners held 33.2% of practices, ahead of hospitals at 30.6%.
Rollover changes who keeps the arbitrage. Example, hypothetical, our arithmetic: a 5x offer on $1 million of EBITDA with 20% rolled over pays $4 million in cash before debt payoff, fees and taxes, plus $1 million of platform equity at the buyer's price. That equity is illiquid and pays only if the platform reaches a later sale. Until then the seller carries its debt and integration risk. See private equity physician roll-ups for how these structures work.
Deal activity. Becker's ASC Review, reporting PESP's 2025 data, counts 148 deals involving outpatient care providers in 2025, of which 119 (80.4%, our arithmetic) were add-ons. Dermatology led outpatient subsectors with 24 deals, ahead of eye care with 22 and oncology with 9. Those three made up 55 deals, or 37.2% of the total (our arithmetic). Deal counts measure activity, not price.
Chart data
| Health IT | 151 |
|---|---|
| Dental care | 149 |
| Outpatient care | 148 |
| Medtech | 117 |
| Behavioral health | 56 |
Source: Private Equity Stakeholder Project, PE healthcare deals 2025 in review
Worked Example: From Operating Income to Adjusted EBITDA at the 8x to 10x Dermatology Tier
Example setup. Two hypothetical practices. Sourced inputs: FOCUS's tier multiples (2026) and Axia's 8.8x median (as of October 28, 2026). Assumptions: margins, depreciation, add-backs and rent. All arithmetic is ours. Basis: every multiple is applied to adjusted EBITDA, the figure a buyer prices. Neither FOCUS nor Axia states whether its EBITDA is adjusted, so this treatment assumes the buyer accepts the add-backs.
Operating income is calculated after depreciation and amortization, after whatever the owner actually paid themselves, and after actual rent and one-time costs. Reported EBITDA adds depreciation and amortization back. Adjusted EBITDA also normalizes owner pay to market replacement cost, removes genuine one-time items and resets related-party rent to market. Each adjustment needs documentation. Buyers reject the weak ones.
Both groups have $20 million of revenue, which places them in FOCUS's regional tier at 8x to 10x. Practice A is mostly medical dermatology. Practice B carries a larger cosmetic and medspa line at a higher margin.
| Line (hypothetical) | Practice A (medical mix) | Practice B (cosmetic-heavy) |
|---|---|---|
| Revenue | $20.0M | $20.0M |
| Operating margin (assumption) | 25% | 30% |
| Operating income, after actual owner pay and rent | $5.0M | $6.0M |
| Add: depreciation and amortization | $0.4M | $0.5M |
| EBITDA (reported) | $5.4M | $6.5M |
| Add: owner pay above market replacement cost | $0.6M | $0.6M |
| Add: one-time legal cost | $0.1M | $0.0M |
| Less: below-market rent on owner-held building reset to market | ($0.2M) | ($0.2M) |
| Adjusted EBITDA | $5.9M | $6.9M |
| Enterprise value at 8x adjusted EBITDA | $47.2M | $55.2M |
| Enterprise value at 10x adjusted EBITDA | $59.0M | $69.0M |
Same revenue, same range, and the values differ by $8.0 million at 8x and $10.0 million at 10x. All of it comes from the $1.0 million gap in adjusted EBITDA. Position inside the range follows FOCUS's tier drivers: centralized management, in-house pathology or Mohs, and a diversified payor base.
Cross-check with closed sales. Both practices fall in Axia's $5 million to $10 million EBITDA band whether measured on reported EBITDA ($5.4M and $6.5M) or adjusted EBITDA ($5.9M and $6.9M), so the band assignment does not depend on Axia's undisclosed EBITDA basis. At the 8.8x median applied to adjusted EBITDA, Practice A is worth $5.9M × 8.8 = $51.92 million and Practice B $6.9M × 8.8 = $60.72 million. Both sit inside their 8x to 10x ranges.
Test the add-backs. Suppose the buyer rejects Practice A's $0.6 million owner-pay add-back because the owner will keep working at the same pay. Adjusted EBITDA falls to $5.3 million and value drops to $42.4 million at 8x (a $4.8 million cut) or $53.0 million at 10x (a $6.0 million cut). In this tier, every $100,000 of add-back moves price by $800,000 to $1.0 million. The add-back schedule often draws more negotiation than the multiple.
Test the stretch case. A sponsor pricing Practice B at Sikich's 11x to 13x would pay $6.9M × 11 = $75.9 million to $6.9M × 13 = $89.7 million, or $6.9 million to $20.7 million above the top of the dermatology tier. Diligence will test that hard. Practice B sits below FOCUS's $10 million EBITDA threshold for the large platform tier, and its cosmetic revenue moves with consumer spending, so buyers will ask for monthly revenue by service line.
Run your own figures in the practice valuation calculator, starting from operating income with every add-back documented. Take the enterprise value to the deal proceeds calculator to see the cash.
Multiple Bridge: Walking a Hypothetical $5.5 Million EBITDA Group to an Offered Range
Example setup. Sourced input: Axia's 8.8x median (as of October 28, 2026). Everything else is hypothetical, including the turn haircut and the rate cut. All arithmetic is ours. Basis: the 8.8x is applied to adjusted EBITDA. The group sits in Axia's $5 million to $10 million band on both reported and adjusted EBITDA.
The group has $30.0 million of revenue and $5.5 million of reported EBITDA, an 18.3% margin. Two owner physicians and one associate. One commercial payer supplies 45% of revenue, and its contract renews 14 months after the planned closing.
Part 1: reported to adjusted EBITDA.
| Step | Adjustment | Running EBITDA |
|---|---|---|
| Reported EBITDA | $5.50M | |
| 1. One-time items | Add $0.30M EHR conversion and $0.10M owner personal expenses | $5.90M |
| 2a. Owner comp | Each owner paid $1.20M against $0.70M market replacement, so add $1.00M | $6.90M |
| 2b. Associate comp | Associate paid $0.20M below market, so deduct $0.20M | $6.70M |
| 3. Rent to market | Owner-held building leased below market, deduct $0.20M | $6.50M |
| Adjusted EBITDA | $6.50M (21.7% margin) |
Step 2a is the largest line and the most fragile. It holds only if both owners sign post-closing employment agreements near $0.70M each. If they keep $1.20M, the add-back disappears, and at 8.8x that removes $8.8 million of value. Step 2b runs the other way. The buyer will pay the associate market rate to keep them, so underpaying staff inflates reported EBITDA.
Part 2: benchmark multiple to offered range. Start from Axia's 8.8x. Assume a buyer deducts 0.5 to 1.5 turns for the 45% payer concentration, giving 7.3x to 8.3x.
| Multiple | Calculation | Enterprise value |
|---|---|---|
| Benchmark, no haircut | $6.50M × 8.8 | $57.20M |
| Top of offered range | $6.50M × 8.3 | $53.95M |
| Bottom of offered range | $6.50M × 7.3 | $47.45M |
The same risk priced through EBITDA. A buyer could hold 8.8x and cut EBITDA instead. A 5% rate cut on the 45% payer is $30.0M × 45% × 5% = $0.675M of revenue. Assuming all of it falls to EBITDA, adjusted EBITDA becomes $5.825M and $5.825M × 8.8 = $51.26M, inside the turn-haircut range.
The red flag is doing both. The EBITDA cut and the low-end multiple together give $5.825M × 7.3 = $42.52M, $4.93M below the bottom of the range, because one risk is counted twice. Ask every bidder to price payer concentration in one place, EBITDA or multiple, and say which.
EV/Sales check. The offered range is $47.45M ÷ $30.0M = 1.58x to $53.95M ÷ $30.0M = 1.80x revenue. Dividing 1.58 by the 21.7% adjusted margin returns 7.3x, so the offer reconciles.
A seller who multiplies reported EBITDA by the benchmark anchors on $5.5M × 8.8 = $48.4M. Documented add-backs push value up and the payer haircut pulls it down. The final price depends on which add-backs survive diligence and how the buyer prices one contract.
Headline Multiple vs Cash at Close: What a 9x Offer Pays in 2026
Every multiple on this page is an enterprise value multiple, a headline price. Ask each bidder to restate its offer as cash at close divided by adjusted EBITDA, and compare on that number.
Example, hypothetical, our arithmetic. Basis: adjusted EBITDA. A 9x headline on $2.0 million of adjusted EBITDA is $18.0 million of enterprise value. With 30% rolled over ($5.4 million) and a $1.8 million earnout, cash at close is $10.8 million before debt payoff, fees and taxes. That is 5.4x EBITDA in cash while the headline reads 9x. The earnout is counted at face value with no discount for risk or delay, and the rollover at the buyer's price though you can't sell it. For context, Sikich's 2026 bands put practices with $1 million to $3 million of EBITDA at 7x to 9x, so 9x is the top of that band. Axia's closed healthcare-sector sales at $2 million to $3 million of EBITDA have a 5.1x median (as of October 28, 2026).
Compare offers on one sheet. Example, hypothetical, our arithmetic, same $2.0 million of adjusted EBITDA:
| Offer | Headline | Rollover | Earnout (face) | Cash at close before debt, fees, taxes | Cash multiple |
|---|---|---|---|---|---|
| Bidder 1 | 9.0x = $18.0M | 30% = $5.4M | $1.8M | $10.8M | 5.4x |
| Bidder 2 | 7.5x = $15.0M | 10% = $1.5M | $0 | $13.5M | 6.75x |
Bidder 2 has the lower headline and pays $2.7 million more at closing. Bidder 1 wins only if the rollover and earnout pay out at or above face value.
What to ask every buyer, in writing:
- Cash at close as its own line, after debt payoff and the working capital adjustment.
- Rollover percentage and the valuation the rollover equity is priced at.
- Earnout metric, measurement period, and who controls the inputs.
- Escrow or holdback amount and release date.
- Debt-like items the buyer plans to deduct from enterprise value.
- The EBITDA figure, its basis (reported or adjusted) and the period the multiple applies to, so you can run the EV/Sales cross-check.
Run each offer through the deal proceeds calculator, value contingent pieces with the earnout value calculator and screen the letter against our LOI and term sheet red flags. The healthcare deal structures guide compares structures side by side.
Who Is Buying: 1,029 PE Healthcare Deals in 2025 and the Strategic Premium
The Private Equity Stakeholder Project tracked 1,029 PE-backed healthcare deals in 2025, involving 420 platform companies.
| Deal type, 2025 (PESP) | Count | Share (our arithmetic) |
|---|---|---|
| Add-on acquisitions | 664 | 64.5% |
| Growth investments | 214 | 20.8% |
| Leveraged buyouts | 151 | 14.7% |
| Total | 1,029 | 100% |
Add-ons outnumbered new buyouts 4.4 to 1 (our arithmetic). Most owners who sell to private equity sell into an existing platform at add-on pricing. The platform premium goes to businesses that become platforms, or to sellers who roll equity into one.
Strategic buyers pay more in some segments. FOCUS's 2026 dashboard reports that corporate buyers in therapeutic and technology-driven sectors paid 20% to 40% higher multiples than financial sponsors on a like-for-like EBITDA basis. Applied to a hypothetical 9x sponsor bid, that is 10.8x to 12.6x (our arithmetic). Cross-border acquirers made up 2.0% of 2025 healthcare deals in the same dashboard, focused on specialty pharma and device innovation. For a device or healthcare technology company, a process without strategic buyers leaves out the top of the range. For a physician practice, the buyer list is mostly sponsors and their platforms.
Practice structure is shifting toward what buyers want. The AMA's 2024 practice benchmark shows 37.2% of physicians in single specialty practices in 2024, down from 45.4% in 2012, and 27.8% in multi-specialty practices, up from 22.1%. The AMA puts the remaining gap at about 9 percentage points, against 23.3 points in 2012 (our arithmetic). Axia, citing the AMA, reports that 6.5% of physicians described their practice as PE-owned in 2024, up from about 4.5% in 2020 and 2022. Buyers pay platform multiples for multi-site, multi-provider groups, and more of the market now looks like that.
Family offices and physician investors writing minority checks into these platforms face the same entry prices sponsors do. See how family offices invest in healthcare.
Decision rule for owners. If your business has real software, data or a tech-enabled service line, argue for a blended comp set and report that line's revenue and margin separately. Damodaran's January 2026 healthcare IT group runs a 48.32% gross margin and a 17.12% EBITDA margin. Your tech line needs margins in that range before the comparison holds.
Decision rule for investors. Sikich reports PitchBook's 12.7x trailing healthcare median as the highest of any sector. Build the case on operating improvement and add-on arbitrage, not on exit multiples rising.
Hospital M&A in 2026: 56 Deals Through Q3 on a 2.5% Operating Margin
Hospital multiples rest on thin earnings. Kaufman Hall's Q3 2026 report (released October 13, 2026) puts year-to-date hospital operating margin at 2.5% including allocations, with nearly 43% of hospitals operating at a loss, both as of August 2026. Non-labor expenses per adjusted discharge rose 6% year to date from 2025, with supply costs up 5% and drug costs up 6% over the same period.
| Hospital M&A metric (Kaufman Hall) | Figure |
|---|---|
| Transactions announced, Q1 / Q2 / Q3 2026 | 22 / 18 / 16 |
| 2026 total through Q3 | 56 |
| All of 2025 | 46, the lowest annual count since Kaufman Hall began tracking in 2011 |
| Q3 2026 vs Q3 2025 | Matched |
| Q3 2026 transacted revenue | $8.2 billion |
| Q3 2026 average seller revenue | About $586 million (Sikich: up from $401 million a year earlier) |
| Megamergers announced in Q3 2026 | 2, the third consecutive quarter with megamergers |
| Divestitures | Nearly one-third of Q3 transactions |
| Acquirers | Not-for-profit organizations were most acquirers in Q3 |
Quarterly counts, the 2026 total through Q3 and the 2025 total as reported by Becker's Hospital Review from Kaufman Hall data. All other rows from the October 13, 2026 Kaufman Hall release, except the prior-year seller size, which comes from Sikich.
Becker's reports Kaufman Hall's definition of a megamerger as a deal in which the smaller party has more than $1 billion of annual revenue. Kaufman Hall says 2026 could become a record year for those deals.
What it means for valuation. Kaufman Hall's 2.5% and Damodaran's 14.05% measure different things: an operating margin after allocations across a broad hospital universe, against the EBITDA margin of 31 listed operators in January 2026. Together they show why buyers price many hospitals on revenue or assets. A 9.5x multiple on a hospital earning near breakeven produces little value, and Buckhead's distressed sales cleared at 0.15x revenue. The 9x to 10x range describes larger systems with stable, positive EBITDA.
Six Inputs to Gather Before You Quote a Multiple
| Input | What to prepare | Why buyers price it |
|---|---|---|
| Earnings band | Trailing twelve months operating income and the bridge to adjusted EBITDA, every add-back documented | Sets your row in Axia, Sikich and Buckhead |
| Specialty tier | The tier your revenue puts you in, where one exists, as in dermatology | FOCUS tiers move 3x to 15x within one specialty |
| Margin by service line | Medical, cosmetic, ancillary and tech lines reported separately | A blended margin hides the line a buyer will discount or pay up for |
| Payer mix | Commercial, government and cash-pay shares, plus any outsized payer and its renewal date | Concentration gets priced as a turn haircut or an EBITDA cut |
| Owner dependence | Provider count, signed provider agreements, post-closing comp terms, revenue tied to the selling physician | Decides whether the owner-pay add-back survives |
| Structure | Cash at close, rollover, earnout and debt-like items deducted from enterprise value | Turns a headline multiple into cash |
Fix the weak inputs before a buyer finds them. See our guide to preparing a healthcare company for sale and the quality of earnings prep checklist. Then go to market with more than one buyer. With several bidders, the market sets the price of each diligence finding. A single buyer sets it alone.
Pressure-Testing a Buyer's Multiple Before You Sign the Letter of Intent
Run every quoted multiple through these seven checks. Each one uses figures already on this page, so you can see where an offer sits before you negotiate.
| Check | How to run it | Reference figure from this page | Push back if |
|---|---|---|---|
| Size band | Place adjusted EBITDA in the Axia and Sikich bands | $2M to $3M EBITDA: Axia 5.1x median, Sikich 7x to 9x | The quote sits well outside your band with no platform rationale |
| Earnings basis | Confirm SDE, reported or adjusted EBITDA, and the twelve-month period | Axia prices SDE below $2M of earnings | The letter does not state the basis in writing |
| EV/Sales identity | Enterprise value ÷ revenue ÷ adjusted EBITDA margin | $40M ÷ $25M = 1.6x, ÷ 20% = 8.0x | The result comes in below the letter's multiple |
| Add-back survival | List each add-back and the buyer's position on it | Practice A: each $100,000 of add-back moves price $0.8M to $1.0M | The owner-pay add-back is rejected while post-closing pay is still open |
| Risk counted once | Ask where payer concentration is priced, EBITDA or multiple | Double-counted case: $42.52M against a $47.45M range floor | The buyer cuts both EBITDA and the multiple for the same risk |
| Cash multiple | Cash at close ÷ adjusted EBITDA | 9x headline = 5.4x cash in the Bidder 1 example | A lower headline from another bidder pays more cash |
| Buyer mix | Count platforms, add-on buyers and strategics in the process | Add-ons 64.5% of 2025 PE deals. Strategic premium 20% to 40% in some sectors | Only one buyer type is at the table |
Order of work. Run the size band and earnings basis checks first, because the rest depend on them. Then reconcile the EV/Sales identity, settle the add-back schedule, and only then compare cash multiples across bidders.
Physician compensation, referral relationships and ownership structure can change what a multiple actually buys, so review healthcare compliance due diligence guide and management services organizations, and see healthcare M&A process guide for how review timing can affect closing. Take the questions those pages raise to your own attorney before you sign.
Questions practice owners and investors ask
What EBITDA multiple does a medical practice sell for in 2026?
Size sets the answer. In Axia Growth's closed healthcare-sector sales (data as of October 28, 2026), medians run from 3.4x seller's discretionary earnings (SDE) below $1 million of SDE to 8.8x EBITDA at $5 million to $10 million and 12.9x above $10 million. Sikich's Q3 2026 update puts physician practices at 5x to 7x below $1 million of EBITDA, rising to 11x to 13x above $5 million of EBITDA. Confirm whether any quote applies to SDE, reported EBITDA or adjusted EBITDA.
Are healthcare valuation multiples going down in 2026?
The market median is. PitchBook's healthcare M&A median, as reported by Sikich, fell from 14.5x EBITDA in 2024 to 13x in 2025 and 11.6x for 2026 year to date in Sikich's Q3 2026 update. Platform pricing held. In the same PitchBook data, the median PE-backed healthcare services deal was 13.6x in 2025 against 13.5x in 2024. Buckhead FMV's control-deal medians moved in a band, not a trend, from January 2023 through October 2026.
Why do bigger healthcare practices get higher multiples?
Buyers pay for infrastructure and margin consistency they would otherwise have to build. FOCUS Investment Banking's 2026 dashboard reports that companies above $10 million of revenue often see a 1.5x to 2x jump in multiples. Buckhead FMV finds deal size is the largest single driver of the multiple. Deals above $200 million of enterprise value sold at a median 11.2x EBITDA and deals below $10 million at 2.8x (January 2023 to October 2026).
How do I check whether a buyer's quoted multiple adds up?
Divide the offered enterprise value by your trailing revenue, then divide by your adjusted EBITDA margin for the same twelve months. The result should equal the multiple in the letter. If it comes out lower, the buyer is pricing less EBITDA than you are and has rejected some of your add-backs. Ask which ones.
Do strategic buyers pay more than private equity?
In therapeutic and technology-driven sectors, yes. FOCUS Investment Banking's 2026 dashboard reports that corporate buyers there paid 20% to 40% higher multiples than financial sponsors on a like-for-like EBITDA basis. Physician practices sell mostly to sponsors and their platforms. Add-ons were 664 of the 1,029 PE-backed healthcare deals PESP tracked in 2025.
Is enterprise value the same as what the seller receives?
No. Enterprise value is the headline price for the whole business. Debt payoff, the working capital adjustment, fees and taxes come out of it. Rollover equity and earnouts pay later or not at all. Ask each bidder for cash at close divided by adjusted EBITDA and compare offers on that number.
Sources
- Aswath Damodaran, NYU Stern, EV/EBITDA multiples by sector (US), data as of January 2026 (primary data)
- Aswath Damodaran, NYU Stern, Price and Enterprise Value to Sales by industry (US), data as of January 2026 (primary data). Columns used: number of firms, EV/Sales, pre-tax operating margin, net margin
- Aswath Damodaran, NYU Stern, Margins by industry (US), data as of January 2026 (primary data). Columns used: gross margin, EBITDA margin
- Buckhead FMV, Healthcare Services M&A Valuation Multiples, 2023-2026: Benchmarks by Segment, Size and Year, 187 U.S. control transactions announced January 1, 2023 through October 31, 2026, drawn from SEC filings, state certificate-of-need and transaction-notice filings, bankruptcy court sale approvals and Medicare cost reports
- Axia Growth, Physician Practice Management and MSOs page, data as of October 28, 2026. Healthcare-sector size-band medians from closed small-business sales over $500K, plus physician employment and practice ownership figures citing PAI-Avalere and the AMA
- Sikich, Q3 2026 US Healthcare M&A Market Update and Year-End Outlook, reporting PitchBook medians, plus Sikich's practice size bands, sub-sector ranges and public hospital comps as of June 30, 2026
- FOCUS Investment Banking, Healthcare EBITDA Multiples: 2026 Dashboard. Findings cited: $10 million revenue threshold, strategic premium, cross-border acquirer share
- FOCUS Investment Banking, Dermatology Practice Valuation: 2026 Benchmarks. Tiers cited: Solo Practice, Small Group, Regional / Mid-Sized Platform, Large Integrated Platform
- Private Equity Stakeholder Project, Private Equity Healthcare Deals: 2025 in Review
- Becker's ASC Review, The outpatient specialties that dominated 2025 deal activity (PESP 2025 data)
- Kaufman Hall, Q3 2026 M&A Quarterly Activity Report press release, October 13, 2026
- Becker's Hospital Review, Kaufman Hall Q3 2026 hospital transaction data
- AMA Policy Research Perspective, Physician Practice Characteristics in 2024